Literature DB >> 7564669

Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation.

C Singaram1, W Ashraf, E A Gaumnitz, C Torbey, A Sengupta, R Pfeiffer, E M Quigley.   

Abstract

Clinical studies suggest that gut disorders are common in Parkinson's disease, but the morphological basis is unknown. Depletion of dopamine-containing neurons in the central nervous system is a basic defect in Parkinson's disease. We compared colonic tissue from 11 patients with advanced Parkinson's disease, 17 with adenocarcinoma (normal tissue was studied), and five who underwent colectomy for severe constipation. Immunohistochemistry was used to stain myenteric and submucosal neurons for dopamine, tyrosine hydroxylase, and vasoactive intestinal polypeptide (VIP). Each class of neurons was quantified as a percentage of the total neuronal population stained for the marker protein gene product 9.5. Nine of the 11 Parkinson's disease patients had substantially fewer dopaminergic myenteric neurons than the other subjects (mean 0.4 [SE 0.2] vs 6.9 [2.3] in controls and 5.7 [2.0] in constipated subjects). There was very little difference between the groups in numbers of tyrosine-hydroxylase and VIP neurons. Two Parkinson's disease patients had similar distributions of all types of neurons, including dopaminergic myenteric neurons, to the controls. High-performance liquid chromatography showed lower levels of dopamine in the muscularis externa (but not mucosa) in four Parkinson's disease patients than in four controls (7.3 [5.1] vs 24.2 [4.6] nmol per g protein), but levels of dopamine metabolites were similar in the two groups. The identification of this defect of dopaminergic neurons in the enteric nervous system in Parkinson's disease may lead to better treatment of colorectal dysfunction in this disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7564669     DOI: 10.1016/s0140-6736(95)92707-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  88 in total

1.  Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue.

Authors:  S Basu; P S Dasgupta
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

Review 2.  Constipation in neurological diseases.

Authors:  K Winge; D Rasmussen; L M Werdelin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

3.  Homeodomain interacting protein kinase 2 regulates postnatal development of enteric dopaminergic neurons and glia via BMP signaling.

Authors:  Alcmène Chalazonitis; Amy A Tang; Yulei Shang; Tuan D Pham; Ivy Hsieh; Wanda Setlik; Michael D Gershon; Eric J Huang
Journal:  J Neurosci       Date:  2011-09-28       Impact factor: 6.167

4.  Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation.

Authors:  L Wang; I Magen; P-Q Yuan; S R Subramaniam; F Richter; M-F Chesselet; Y Taché
Journal:  Neurogastroenterol Motil       Date:  2012-07-11       Impact factor: 3.598

Review 5.  The bowel and beyond: the enteric nervous system in neurological disorders.

Authors:  Meenakshi Rao; Michael D Gershon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-07-20       Impact factor: 46.802

6.  Morphology of VIP/nNOS-immunoreactive myenteric neurons in the human gut.

Authors:  A Brehmer; F Schrödl; W Neuhuber
Journal:  Histochem Cell Biol       Date:  2005-11-19       Impact factor: 4.304

7.  Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease?

Authors:  R J Phillips; G C Walter; S L Wilder; E A Baronowsky; T L Powley
Journal:  Neuroscience       Date:  2008-03-18       Impact factor: 3.590

Review 8.  The pathology roadmap in Parkinson disease.

Authors:  D James Surmeier; David Sulzer
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

9.  Alpha-synuclein immunohistochemistry of gastrointestinal and biliary surgical specimens for diagnosis of Lewy body disease.

Authors:  Shinji Ito; Masaki Takao; Hiroyuki Hatsuta; Kazutomi Kanemaru; Tomio Arai; Yuko Saito; Masashi Fukayama; Shigeo Murayama
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

10.  Impaired gastric myoelectrical activity in patients with Parkinson's disease and effect of levodopa treatment.

Authors:  Ching-Liang Lu; Din-E Shan; Chih-Yen Chen; Jiing-Chyuan Luo; Full-Young Chang; Shou-Dong Lee; Han-Chang Wu; J D Z Chen
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.